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Patient’s characteristics, drug utilization patterns and resource utilization were 
analyzed. Results: Data were available for a sample of 244 eligible patients. The 
average age of the study population was 24.3 years (SD= 12.5). While the maxi-
mum medication possession ratio (MPR) for alternate month administration is 
50%, patients on TIP had an average MPR of 52.8%, while patients on TIS and OTF 
had an average MPR of 41.4% and 39.7%, respectively. Treatment persistence at 3 
months was estimated at 85.5%, 69.0%, and 65.2% for patients on TIP, TIS, and OTF, 
respectively. Treatment persistence at 6 months was estimated at 78.4%, 62.8%, 
and 56.5%, respectively for patients on TIP, TIS, and OTF. Higher CF medication 
treatment costs with TIP were partially offset by lower costs associated with the 
use of antibiotics, other medications and additional health care resource utiliza-
tion. The median monthly cost per patient in terms of other medications was of 
$1,159 (including $79 for other antibiotics), $1,350 ($172), and $1,495 ($240) for 
patients on TIP, TIS, and OTF, respectively. The median monthly additional health 
care resource utilization cost per patient was estimated at $56, $188, and $220, 
respectively for TIP, TIS and OTF cohorts. ConClusions: In a real life setting, TIP 
was associated with a high level of treatment adherence and limited utilization 
of additional health care resources.
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AdhereNce to ANtIretrovIrAl therAPy AmoNg hIv-INfected PAtIeNts 
AtteNdINg to A UNIversIty INfectIoUs dIseAses clINIc IN veNezUelA
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objeCtives: To determine adherence levels and factors influencing adherence 
to antiretroviral therapy among HIV-infected patients in Venezuela. Methods: 
A sample of 46 HIV-infected HIV patients attending an infectious diseases clinic at 
the Central University of Venezuela were interviewed by the investigators for 20 to 
25 minutes. The interview was guided by a structured questionnaire that included 
questions on sociodemographic and clinical characteristics, medication use, and 
health behaviors. Adherence was assessed retrospectively based on a 4-day recall 
as used in Adult AIDS Clinical Trials Group (AACTG) follow up questionnaire. All 
data analyses were performed using SSPS for Windows Version 19.0. Results: Of 
46 participants, 30 (65.2%) were male and 16 (34.8%) were female. The mean age 
was 43.17 years ( Range 26-73, SD= 9,790). From 46 participants 69.7% reported 
adherence ≥ 95%. Forgetting to take the medications, alcohol use, and problems 
with the medications supply were main barriers for adherence in the present 
study. ConClusions: A group of patients at this clinic reported unsatisfactory 
adherence. Forgetfulness was reported to be the major cause of non-adherence. 
Since adherence to antiretroviral therapy in critical to achieve optimal treatment 
outcomes, health care providers must identify possible barriers to adherence at the 
earliest and provide appropriate solutions.
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objeCtives: Hepatitis C virus (HCV) infection treatment completion is a key success 
factor for achieving optimal clinical outcomes. The objective of this study was to assess 
HCV treatment completion rates in a real life setting. Methods: A retrospective study 
of the Quebec provincial drug reimbursement program (RAMQ) was conducted using 
a random sample of patients who filled at least one script at the pharmacy for an HCV 
medication (pegylated interferon and ribavirin (peg-Riba) +/- boceprevir or telaprevir) 
from January 2007 to December 2012. Treatment completion rates were calculated at 
week 12, 24 and 28 according to HCV medication type in order to assess the proportion of 
patients treated beyond the 12-week futility threshold and the minimal expected treat-
ment duration of 24 weeks (28 weeks for Peg-Riba + boceprevir). Results: A total of 1,081 
patients who used at least one HCV medication were included in the study. The average 
age was 46.4 years (SD= 10.7) and the proportion of men was higher (64.8%). During the 
study period, the number of patients who used Peg-Riba only, Peg-Riba + boceprevir and 
Peg-Riba + telaprevir was 1,029 (95.2%), 50 (4.6%) and 18 (1.7%) respectively. The propor-
tion of patients on Peg-Riba only who completed at least 12 and 24 weeks of treatment 
was 89.7% and 62.2% respectively. There were 96.0% and 58.0% of patients on Peg-Riba 
+ boceprevir who remained on treatment at week 12 and 28 respectively. The percent-
age of patients on Peg-Riba + telaprevir on treatment at week 12 and 24 was 50.0% and 
11.1%, respectively. ConClusions: The proportion of HCV patients who were still on 
treatment decreased with time with high discontinuation rates especially after week 12. 
Treatment completion was not achieved by a significant proportion of patients, regard-
less of HCV medications.
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objeCtives: Over the course of last decade the introduction of highly effective 
antiretroviral (ARV) therapies has transformed a once life-threatening disease into 
a chronic condition. However, maintaining patient adherence to therapy, in the long-
term, is challenging. Despite the enormous benefits offered by current ARVs, evi-
dence suggests that adherence to treatment regimens remains an issue. Numerous 
factors have been identified which compromise long-term adherence, including 
drug-drug interactions, therapy regimen, side-effects, and the overall demands of 
therapy. The aim of this study is to further understanding of the determinants 
of treatment satisfaction for HIV patients receiving ARV therapies. Methods: A 
programme of research was developed in order to firstly establish the relation-
ship between patients’ views of their current therapies and the adherence to ARVs. 
INfectIoN – Patient-reported outcomes & Patient Preference studies
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objeCtives: To determine the comparative effectiveness of different interven-
tions for improving antiretroviral medication adherence in low-income set-
tings. Methods: We obtained individual patient data from all randomized trials 
that have evaluated an adherence intervention to promote antiretroviral adher-
ence within low-income countries. We created a treatment network of the differing 
interventions by pooling the individual patient data from comparable treatments 
and comparing them across the individual interventions using a Bayesian net-
work meta-analysis approach. Outcomes included self-reported adherence and 
viral suppression. Results: We obtained data on 11 randomized, involving 5432 
patients. Interventions included daily and weekly text messaging, calendars, peer 
supporters, alarms, counseling, and basic clinical care. For self-reported adher-
ence, we found compelling evidence for the role of weekly text messages (Odds 
ratio [OR] 1.57, 95% Confidence Intervals [CI] 1.22-2.02), counseling (OR 1.43, 95% CI, 
1.06-1.94), and peer supporters (OR 1.72, 95% CI, 1.28-2.29). We found no compel-
ling evidence for daily text messaging, alarms, calendars, or unsupported clinical 
care. Results were similar when using viral suppression as an outcome, although 
not all trials reported viral outcomes. Treatment supporters (OR 1.36, 95% CI, 1.02-
1.82) and weekly text messages (OR, 1.56, 95% CI, 1.01-2.39) were superior to basic 
clinical care. ConClusions: Using individual patient data allowed us to increase 
precision to determine what interventions appear to work. Several common recom-
mendations for improving adherence are unsupported by the available evidence. 
These findings should influence guidance documents on improving antiretroviral 
adherence in poor settings.
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objeCtives: Adherence to ART is a key success factor for achieving optimal 
clinical outcomes in HIV disease. The objective was to assess differences in 
compliance rates and health care resource utilization between patients receiv-
ing a once daily single tablet regimen (STR) vs. a multiple tablets per day regi-
men (MTR). Methods: This retrospective study included patients covered by 
the Quebec provincial drug reimbursement program (RAMQ) who have received 
at least one script for an ART from January 1st, 2006 to June 30th, 2012. For each 
patient, the index date was defined as the date of the first script for an ART and 
compliance rates were estimated over a 1-year period. Patients were considered 
compliant if their medication possession ratio (effective treatment duration 
over expected treatment duration) was equal or greater to 90%. Medical costs 
(hospitalizations and ER, outpatient clinic, ICU and physician’s visits) were com-
pared between the STR group vs. the MTR group. Regression analyses were per-
formed to assess the relationship between compliance, hospitalization rates and 
medical costs with the ART regimen, adjusting for age, gender, comorbidities 
scores, mental disorders diagnosis and drug and alcohol abuses. Results: The 
study included 4,996 HIV patients (mean age: 42.4 years, 74.8% males). A higher 
proportion of patients were compliant (88.4% vs. 75.8%) in the STR group com-
pared to the MTR group (p< 0.001). Patients receiving a MTR were 2.0-fold more 
likely to be non-compliant than patients receiving a STR (p< 0.001). Moreover, 
hospitalization rates (25.8% vs. 15.9%, p< 0.001) and medical costs (CAD$2,785 
vs. CAD$1,909, p= 0.008) were higher for patients receiving a MTR than a 
STR. Linear regression analyses also showed a positive relationship between 
MTR (vs. STR) and hospitalization rates (β = 0.081,p= 0.001) and medical costs 
(β = 0.151, p< 0.001). ConClusions: Patients receiving a STR are more 
compliant than patients on a MTR and have lower hospitalization rates and 
medical costs.
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tobrAmycIN Powder for INhAlAtIoN for the treAtmeNt of cystIc 
fIbrosIs: ANAlysIs of the rAmQ dAtA
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Desforges J.3, Sagkriotis A.2
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objeCtives: To describe treatment patterns and measure real-world outcomes 
with tobramycin powder for inhalation (TIP), tobramycin inhalation solu-
tion (TIS), and other tobramycin formulations (OTF), using the provincial pub-
lic drug reimbursement program database of the Régie de l’assurance maladie du 
Québec(RAMQ). Methods: Patients with a diagnosis of CF covered by the RAMQ 
drug reimbursement program who had used TIP, TIS, or OTF on at least one 
occasion during the period from January 1st 2011 to June 30th 2012 were selected. 
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objeCtives: Electronic Patient Reported Outcomes (PRO) provide quick and reli-
able assessment of patients’ health-related quality of life (HRQL). An electronic 
version of the PROQOL-HIV questionnaire was developed, and its face validity 
and reliability were assessed using standard psychometric methods. Methods: 
A total of 70 French outpatients (63% males, mean age 47 years) were recruited. 
Hard copy and electronic questionnaires were completed in a randomized cross-
over design (2-7 day interval). Biomedical data were collected. Questionnaire ver-
sion and order effects were tested on full scale scores in a two-way ANOVA with 
patients as random effects. Test-retest reliability was evaluated using Pearson and 
intra-class correlation coefficients (with 95% confidence interval) for each dimen-
sion. Usability testing was carried out from patients’ survey reports, specifically: 
general satisfaction, ease of completion, quality and clarity of user interface (UI) 
and self motivation for electronic measuring to monitor HRQL in clinical follow-
up. Results: Questionnaire version and administration order effects (N= 58 
complete cases) were not significant at the 5% level, nor interacting together 
(p= 0.940). Reliability indices were acceptable, with Pearson correlations above 
0.7 and intra-class correlations ranging from 0.696 to 0.926, and scores were not 
statistically different between the two versions. On 77% of complete surveys, 57% 
of patients reported being satisfied and interested in electronic assessment of 
their HRQL in clinical follow up. Individual ratings of PROQOL-HIV user interface 
(85-100% of positive responses) confirmed UI clarity and usability. ConClusions: 
The electronic PROQOL-HIV introduces minor modifications compared to the 
original paper-based version, following ISPOR ePRO Task Force guidelines, and 
it showed good reliability and face validity. Patients can complete the computer-
ized PROQOL-HIV questionnaire as intended and scores delivered from paper or 
electronic version share comparable accuracy and interpretation.
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chIldhood vAccINAtIoN
Lehocká L., Malovecká I., Minariková D., Foltan V.
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objeCtives: The immunization is currently one of the most discussed topics in 
the population and the number of its opponents is increasing. Methods: Opinion, 
awareness and knowledge of parents (n-parents= 240, n-children= 463) about child-
hood immunization through self-reported technique of a questionnaire survey was 
conducted, with respect of gender, age, education and profession of parents in 
regard of their professional connection with health care in case of obligatory and 
recommended childhood vaccination. Results: In case of obligatory childhood 
vaccination all evaluated parameters influence and change opinion, awareness 
and knowledge of parents. Age (p< 0,01, Degree of freedom (df)= 10, Chi-squared 
distribution (χ ²)= 81,08, table value of Chi-squared distribution (tχ ²)= 23,21); gender 
(p< 0,01, df= 2, χ ²= 12,87, tχ ²= 9,21); education (p< 0,01, df= 10, χ ²= 79,11, tχ ²= 23,21); 
health care profession (p< 0,01, df= 2, χ ²= 13,75, tχ ²= 9,21. In case of recommended 
childhood vaccination all analyzed parameters influence and change parents’ 
opinion, awareness and knowledge, except for those working in health care. Age 
(p< 0,01, df= 5, χ ²= 13,29, tχ ²= 15,09); gender (p< 0,01, df= , χ ²= 79,82, tχ ²= 13,28); educa-
tion (p< 0,01, df= 4, χ ²= 49,10, tχ ²= 13,28); health care profession (0,01< p< 0,03, df= 1, 
χ ²= 4,85, tχ ²= 6,64). ConClusions: Analysis confirms that age, gender, education 
and profession connected with health care influence and change parents’ opinion, 
awareness and knowledge about obligatory childhood vaccination. Regarding the 
recommended childhood vaccination, age, gender and education influence and 
change parents’ opinion, awareness and knowledge, although a profession con-
nected with health care neither influences, nor changes opinion, awareness and 
knowledge of the parents.
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objeCtives: Both chronic HCV infection and current treatments negatively impact 
patient reported outcomes. PegIFN/RBV-based therapies decrease general HRQoL 
scores 10%-30% (on SF-36). Psychometric analyses of validity, responsiveness, 
and MID for the HCV-specific HCV-PRO instrument were performed. Methods: 
Responses to the HCV-PRO (presented ILC2012), the SF-36, and EuroQol-5D 
(EQ-5D)+VAS were analyzed in the M11-602 trial of pegIFN/RBV with placebo 
(n= 11) or DAA: ABT-450/ ritonavir (n= 24), ABT-072 (n= 23), or ABT-333 (n= 16). 
DAAs were administered for 12 weeks, pegIFN/RBV for 48 weeks. PRO instru-
ments were administered at baseline, week 8, end of DAA treatment (EODT), end 
of pegIFN/RBV treatment (EOT), and posttreatment week 24 (PT24). Convergent 
validity of HCV-PRO total score (range 0-100) was assessed through correlation 
(Pearson’s) to SF-36 MCS/PCS and EQ-5D VAS scores. Discriminant validity was 
assessed by dichotomizing HCV-PRO responses on EQ-5D Anxiety/Depression 
dimension severity (none vs. some) and treatment emergent depression/fatigue 
adverse events (MedDRA terms). Responsiveness was assessed through analyses 
of effect size (ES). MID was assessed by standard error of the mean (SEM) and 
The initial step involved undertaking a review of published literature detail-
ing HIV patients’ experiences of receiving ARV therapy. These findings formed 
the basis of a meeting of leading European HIV clinical experts, prominent HIV 
organisation representatives and patients themselves. Results: The literature 
revealed numerous factors such as convenience, tolerability, relationship with 
physician and disease characteristics which influences patients’ satisfaction 
with treatment. Discussion between the clinicians, representative from patient 
organisations emphasised the importance of patient preferences as they relate 
to adherence with HIV therapy. This additional insight emphasised the under-
recognised role played by individual differences and therapeutic knowledge 
in defining attitudes to treatments. ConClusions: Treatment satisfaction is 
a complex issue. The work undertaken so far has highlighted that despite the 
advances in ARVs there are still concerns for PLWH. The next stage of research 
involves undertaking a series of in-depth qualitative interviews with patients 
across Europe and examining attributes of HIV treatment using the discrete 
choice experiment methodology.
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objeCtives: To determine parental preferences concerning rotavirus vaccination 
for their newborn baby, and to calculate the potential vaccination coverage for dif-
ferent vaccine scenarios. Methods: A Discrete Choice Experiment (DCE) question-
naire was sent to the parents of 1,250 newborns aged 6 weeks in The Netherlands. 
The DCE included nine D-efficient designed choice tasks. Panel-mixed-logit models 
were used to estimate the relative importance of the five included rotavirus vaccine 
attributes; vaccine effectiveness, frequency of severe side effects, protection dura-
tion, location of vaccine administration, out-of-pocket costs. The potential uptake 
or vaccine coverage was calculated for different vaccine scenarios. Results: All 
attributes showed a significant estimate (P< .05). Parents were more likely to get 
their newborn vaccinated if the vaccine effectiveness increased, parents preferred 
a frequency of 1 in 1,000,000 children that suffer from severe side effects over a 
frequency of 1 in 10,000. Protection duration of 3 years was preferred over 1 year 
and parents preferred to get their child vaccinated at the GP’s office. Finally, increas-
ing out-of-pocket costs were associated with decreased willingness to vaccinate. 
With respect to the relative importance of these attributes, vaccine effectiveness 
was most decisive for parents, followed by out-of-pocket costs, protection duration 
and frequency of severe side effects. Vaccination coverage rates ranged between 
22.8% for the least preferred vaccine scenario and 87.5% for the most preferred 
scenario. ConClusions: When deciding whether to vaccinate their newborn baby 
against the rotavirus, parents are mostly driven by the effectiveness of the vaccine, 
the out-of-pocket costs, protection duration and the frequency of severe side effects. 
Differences in vaccine scenarios resulted in a large range in expected vaccination 
coverage. Therefore, the context and content of the implementation strategy of the 
vaccination is expected to strongly affect the vaccination coverage. Specifically 
requesting an out-of-pocket payment of parents should be considered carefully if 
a high vaccine coverage is desired.
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objeCtives: To examine the value of adding simeprevir (SMV) to peginterferon 
and ribavirin (PR) for treatment of chronic hepatitis C virus infection using patient-
reported outcomes (PRO) and their concordance with virology endpoints and 
adverse events (AEs). Methods: Patients rated severity of fatigue (FSS), depres-
sive symptoms (CES-D), and impairment in functioning (WPAI:HepC Productivity, 
Activity, Absenteeism) at baseline and throughout treatment/follow-up in three 
randomized, double-blind trials comparing addition of SMV or Placebo (PBO) dur-
ing initial 12 weeks of PR treatment. PR was administered for 48 weeks (PBO group) 
and either 24 or 48 weeks (SMV group) (response-guided therapy [RGT]). Analysis 
of pooled data from the trials using a piecewise-linear mixed model compared 
the area-under-the-curve from baseline to Wk60 (AUC60) between SMV/PR and 
PBO/PR for each PRO score. Subgroup analyses evaluated impact of Sustained 
Virologic Response 12 weeks post-treatment (SVR12), fibrosis level, and RGT on 
PRO scores. Results: Of 1178 patients studied, analyses included 768 SMV/PR- and 
393 PBO/PR-treated patients. 87.5% of the SMV/PR group met RGT and completed 
treatment in 24 weeks. Fatigue and anaemia AEs were comparable in both groups but 
FSS scores show clinically important increases in fatigue, lasting 6.9 weeks longer 
with PBO/PR (p < 0.001). No significant differences were observed for Absenteeism. 
Mean scores for all other PRO endpoints worsened from baseline to Wk4 in both 
groups and remained impaired to Wk24 (SMV/PR) and Wk48 (PBO/PR), resulting 
in significantly lower AUC60and fewer weeks with clinically important worsening 
scores with SMV/PR. PRO scores indicated better outcomes for patients who met RGT 
criteria or achieved SVR12; differences in PRO scores associated with fibrosis level 
were only observed in the PBO/PR group. ConClusions: Greater efficacy of SMV/
PR enabled reduced treatment duration and less time with PR-related side effects 
without adding to the severity of side-effects during treatment.
